Clinical Trial Detail

NCT ID NCT02304458
Title Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors National Cancer Institute (NCI)
Indications

rhabdomyosarcoma

neuroblastoma

Advanced Solid Tumor

non-Hodgkin lymphoma

Hodgkin's lymphoma

medulloblastoma

osteosarcoma

Therapies

Nivolumab + Ipilimumab

Age Groups: adult child

No variant requirements are available.